Aug. 20, 2025 -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today applauded recent U.S. Senate legislative support for expanding clinical trial endpoints beyond abstinence in substance use disorder treatments, including Alcohol Use Disorder (AUD). The U.S. Senate’s move to encourage the FDA to develop new endpoints for AUD, s

19 August, 2025 – Santhera Pharmaceuticals (SIX: SANN) announces the signing of an exclusive agreement with Uniphar to manage the distribution of AGAMREE® (vamorolone) in the United Arab Emirates, the Kingdom of Saudi Arabia, Kuwait, Oman and Bahrain, for the treatment of Duchenne muscular dystrophy (DMD) in patients four years of age and older. Sales are expected to begin on a named patient basis in Q1 2026, with broader commercial sales anticipated in late 2026 following market authorization

New hope for millions of glaucoma patients as funding advances surgical access to the uveoscleral pathway Aug. 20, 2025 -- Iantrek, Inc., a pioneer in bio-interventional ophthalmic surgery (BIOS), today announced the close of a $42 million Series C financing round, which will fund the U.S. commercial launch of AlloFlo™ Uveo, a first-of-its-kind surgical solution targeting the uveoscleral pathway, as well as broader pipeline expansion. The Series C was led by U.S. Venture Partners (USVP), joi

Aug. 20, 2025 -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) today announces the completion of patient enrollment of SANOVO, a China Phase III study of ORPATHYS® (savolitinib) and TAGRISSO® (osimertinib) as a first-line treatment in certain non-small cell lung cancer (“NSCLC”) patients whose tumors harbor epidermal growth factor receptor (“EGFR”) mutation and MET overexpression. The last patient was enrolled on August 18, 2025. This Phase III trial is a blinded, randomiz

Aug. 19, 2025 -- COUR Pharma, a clinical-stage biotechnology company developing first-in-class, disease-modifying therapies to treat autoimmune diseases, today announced that the first patient has been dosed in the Phase 1b/2a clinical trial for CNP-103, a tolerogenic nanoparticle therapy in development to address the underlying autoimmunity associated with type 1 diabetes (T1D). “The initiation of this trial is important for patients, as we believe our approach to antigen-specific immune toler

Aug. 19, 2025 -- Trethera Corporation (“Trethera”), a clinical stage biopharmaceutical company developing first-in-class therapies for cancer and autoimmune diseases, announced today that it has been awarded a $3 million Small Business Innovation Research (SBIR) grant from the National Institute of Health (NIH). The award evaluates Trethera’s lead candidate, TRE-515, for the treatment of systemic lupus erythematosus (SLE, or ‘lupus’)—a chronic and debilitating autoimmune disease. Trethera wi

Acquisition Poised to Accelerate Life-Saving Interventions, Combining Academic Excellence with Real-World Innovation to Address Global Addiction Crises and Unlock Multi-Billion Market Opportunities Aug. 19, 2025 --- Branded Legacy, Inc. (OTC: BLEG), a leading diversified holdings company dedicated to pioneering health and wellness solutions, today announced a groundbreaking strategic partnership between its wholly-owned subsidiary, Bio-Legacy Evaluative Group, and McMaster University, one of t

-- Achieved Primary Endpoint with 30mg Dose of RE104 Demonstrating 23.0-Point Reduction from Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) Score on Day 7, a 5.8-Point Greater Reduction Than Patients Treated with 1.5mg Dose (p=0.0094) -- -- Clinically Meaningful Reductions in MADRS Observed for RE104 30mg on the First Day Following Administration and Maintained Through Day 28 Follow-Up -- -- RE104 Observed to be Generally Well-Tolerated with No Serious Adverse Events; 92.7% of Pat

- Angitia abstracts selected for two oral presentations and three posters - Angitia collaborator also selected for poster presentation Aug. 19, 2025 -- Angitia Biopharmaceuticals, a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for serious musculoskeletal diseases, today announced that data from its ongoing program evaluating AGA2115 for the treatment of osteogenesis imperfecta (OI) will be presented at the American Society for Bone and

U.S. FDA has placed a clinical hold on the Phase 2b study as it reviews data submitted by BiomX on third-party nebulizer used to deliver BX004; no concerns were raised in the clinical hold notification regarding the BX004 drug candidate Enrollment and dosing of patients outside the US is continuing in accordance with protocol Aug. 19, 2025 -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies targeting s